• Approximately 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, yet no approved off-the-shelf solution capable of regenerating hyaline-like cartilage is currently available in the U.S. market
• Regentis’ GelrinC(R) is a cell-free hydrogel implant designed to repair focal knee cartilage defects in a single approximately 10-minute procedure, with CE Mark approval in Europe and a pivotal U.S. FDA trial now more than 50% enrolled
• A newly patented solvent-free manufacturing process that increases GelrinC(R) production yield by 400% signals Regentis’ preparation for commercial scale-up as clinical and regulatory milestones approach

Knee cartilage damage remains one of the most stubborn problems in orthopedic medicine. Unlike many other tissues in the body, articular cartilage has little natural ability to heal because it lacks both direct blood supply and the biological machinery required for meaningful regeneration. For decades, treatment options have reflected that limitation. Microfracture, the long-standing standard of care, attempts to stimulate repair by drilling into the underlying bone in an attempt to mimic a repair trigger. It can provide short-term symptom relief, but long-term cartilage durability remains a recognized challenge with standard treatment. More advanced cell-based therapies exist, but they introduce substantial complexity, cost, manufacturing requirements, and long procedural delays that limit broader adoption. Despite roughly 472,500 arthroscopic knee procedures in the U.S. each year involving knee cartilage damage, the market still lacks an approved, ready-to-use truly regenerative solution capable of combining procedural simplicity with sustained long-term outcomes. Regentis is positioning durability as a central differentiator, with clinical data demonstrating sustained outcomes over extended follow-up periods.

Regentis Biomaterials (NYSE American: RGNT) is targeting that gap with GelrinC(R), its lead regenerative cartilage repair platform designed as a cell-free alternative to conventional…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com

MissionIR is powered by IBN

This contant was orignally distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Regentis Biomaterials Ltd. (NYSE American: RGNT) and the Off-the-Shelf Opportunity in Knee Cartilage Repair.